keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
KSL-128114, a peptide inhibitor of the membrane regulator syntenin (Ki = 300 nM), notably diminishes the viability of A2058 melanoma and patient-derived glioblastoma multiforme (GBM) cells in a concentration-dependent manner. Furthermore, when administered at 50 µM, KSL-128114 elevates survival times in a patient-derived xenograft (PDX) mouse model of GBM, where mice were implanted intracranially with patient-derived GBM cells pre-cultured with KSL-128114.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | $ 55.00 | |
5 mg | Inquiry | $ 244.00 | |
10 mg | Inquiry | $ 428.00 | |
25 mg | Inquiry | $ 939.00 |
Description | KSL-128114, a peptide inhibitor of the membrane regulator syntenin (Ki = 300 nM), notably diminishes the viability of A2058 melanoma and patient-derived glioblastoma multiforme (GBM) cells in a concentration-dependent manner. Furthermore, when administered at 50 µM, KSL-128114 elevates survival times in a patient-derived xenograft (PDX) mouse model of GBM, where mice were implanted intracranially with patient-derived GBM cells pre-cultured with KSL-128114. |
Synonyms | Ac-rRrGrKkRrSHWX1X2DI-OH (X1=tert-Leucine; X2=Cyclohexylglycine) |
Molecular Weight | 2201.60 |
Formula | C96H165N39O21.XCF3COOH |
keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 1 mg/ml
PBS pH 7.2: 10 mg/ml
DMF: 1 mg/ml
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
KSL-128114 TFA Ac-rRrGrKkRrSHWX1X2DI-OH (X1=tert-Leucine; X2=Cyclohexylglycine) inhibitor inhibit